LYTIX
vs
Oslo OBX
Over the past 12 months, LYTIX has underperformed Oslo OBX, delivering a return of -9% compared to the Oslo OBX's 16% growth.
Stocks Performance
LYTIX vs Oslo OBX
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
FR |
Pharnext SCA
OTC:PNEXF
|
||
US |
Abbvie Inc
NYSE:ABBV
|
||
US |
Amgen Inc
NASDAQ:AMGN
|
||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
||
US |
E
|
Epizyme Inc
F:EPE
|
|
AU |
CSL Ltd
ASX:CSL
|
||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
||
US |
S
|
Seagen Inc
F:SGT
|
|
NL |
argenx SE
XBRU:ARGX
|
Performance Gap
LYTIX vs Oslo OBX
FR |
Pharnext SCA
OTC:PNEXF
|
||
US |
Abbvie Inc
NYSE:ABBV
|
||
US |
Amgen Inc
NASDAQ:AMGN
|
||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
||
US |
E
|
Epizyme Inc
F:EPE
|
|
AU |
CSL Ltd
ASX:CSL
|
||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
||
US |
S
|
Seagen Inc
F:SGT
|
|
NL |
argenx SE
XBRU:ARGX
|
Performance By Year
LYTIX vs Oslo OBX
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
FR |
Pharnext SCA
OTC:PNEXF
|
||
US |
Abbvie Inc
NYSE:ABBV
|
||
US |
Amgen Inc
NASDAQ:AMGN
|
||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
||
US |
E
|
Epizyme Inc
F:EPE
|
|
AU |
CSL Ltd
ASX:CSL
|
||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
||
US |
S
|
Seagen Inc
F:SGT
|
|
NL |
argenx SE
XBRU:ARGX
|
Competitors Performance
Lytix Biopharma AS vs Peers
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
HR |
C
|
CROBEX
INDX:CRBEX
|
|
SA |
T
|
Tadawul All Share
INDX:TASI
|
|
TH |
S
|
SET Index
INDX:SET
|
|
ID |
J
|
Jakarta Composite Index
INDX:JKSE
|
|
GR |
A
|
Athens General Composite
INDX:ATG
|
|
BR |
B
|
BOVESPA
INDX:BVSP
|
|
AR |
S
|
S&P Merval
INDX:MERV
|
|
MX |
M
|
Mexico S&P/BMV IPC
INDX:MXX
|
|
CZ |
P
|
PX Prague Stock Index
INDX:PX
|
|
RU |
M
|
MOEX Russia
INDX:IMOEX
|
Lytix Biopharma AS
Glance View
Lytix Biopharma AS develops novel drugs for the treatment of resistant bacterial and fungal infections, as well as oncology treatments. The company is headquartered in Oslo, Oslo. The company went IPO on 2021-06-14. The firm's product, LTX-315, is a oncolytic molecule representing a new and superior in situ therapeutic vaccination principle to boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapy. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The firm serves customers domestically.